Olapar 150 mg (Olaparib) Tablets

Olaparix 150 (Olaparib) is a targeted anticancer medicine belonging to the class of Poly (ADP-ribose) Polymerase (PARP) inhibitors. It is designed to interfere with the DNA repair process in cancer cells, particularly in patients with inherited or acquired BRCA gene mutations. By preventing cancer cells from repairing damaged DNA, Olaparib may help slow disease progression and support long-term disease control in appropriately selected patients.

It is commonly prescribed by oncology specialists for the treatment and maintenance therapy of specific forms of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. The therapeutic benefits and treatment outcomes depend on individual patient characteristics, genetic status, and clinical evaluation.

Key Therapeutic Uses:

• Maintenance treatment of certain types of advanced ovarian cancer that have responded to platinum-based chemotherapy.
• Treatment of eligible patients with BRCA-mutated HER2-negative breast cancer.
• Maintenance therapy for selected patients with germline BRCA-mutated metastatic pancreatic cancer.
• Management of specific cases of metastatic castration-resistant prostate cancer associated with homologous recombination repair (HRR) gene mutations.
• Supports personalized cancer treatment strategies through targeted molecular therapy.

Important: This medicine should be used only under the supervision of a qualified healthcare professional experienced in oncology treatment.

Active Pharmaceutical Ingredient (API):

• Olaparib INN – 150 mg

Composition:
Each film-coated tablet contains:

• Olaparib INN 150 mg as the active ingredient.

Olaparib is a potent PARP inhibitor that selectively targets cancer cells with impaired DNA repair pathways, thereby enhancing treatment precision while minimizing effects on healthy cells.

Dosage Form:

• Film-Coated Tablet

Strength:

• 150 mg

Pack Size:

• Bottle containing 120 tablets

For detailed information regarding inactive ingredients and excipients, refer to the product labeling or consult a healthcare professional.

The dosage and duration of treatment with Olaparix 150 (Olaparib) should be determined by a qualified oncology specialist based on the patient's clinical condition, treatment response, and overall health status.

Administration Guidelines:

• Take the tablets exactly as prescribed by your healthcare provider.
• Swallow the tablets whole with a glass of water.
• Do not crush, break, split, or chew the tablets.
• The medicine may be taken with or without food.
• Try to take the doses at approximately the same time each day to maintain consistent therapeutic levels.

Missed Dose Instructions:

• If you miss a dose, skip the missed dose and take the next scheduled dose at the regular time.
• Do not take two doses together or take an extra dose to compensate for a missed dose.

If Vomiting Occurs:

• If vomiting occurs after taking the medicine, do not take an additional dose.
• Continue with the next scheduled dose as directed by your healthcare provider.

Dose Modifications:

• Dose interruption or reduction may be necessary in patients who develop significant adverse reactions.
• Patients with renal impairment may require dosage adjustments based on medical assessment.
• Regular monitoring of blood counts and overall clinical status may be recommended during treatment.

Important Usage Information:

• Use this medicine strictly under medical supervision.
• Do not discontinue treatment without consulting your treating physician.
• Inform your healthcare provider about all medicines, supplements, and herbal products you are currently taking.
• Attend all scheduled follow-up appointments and laboratory monitoring sessions as advised.

Disclaimer: The dosage regimen may vary depending on the specific cancer type, genetic profile, treatment goals, and individual patient factors. Always follow the instructions provided by your oncology specialist.